Synergy Pharmaceuticals Inc. (NASDAQ:SGYP) today announced that it has
reached the halfway mark for total enrollment in the first pivotal phase
3 trial of plecanatide in patients with chronic idiopathic constipation
The trial is currently being conducted at 180 sites and has randomized
approximately 675 CIC patients.
for Synergy Pharmaceuticals Reaches Halfway Mark for the First Pivotal Phase 3 Trial of Plecanatide in Patients with Chronic Idiopathic Constipation investment picks